Dr. Statland, a key figure among Statland Medical Group Doctors, is renowned for his extensive research in neuromuscular diseases. His work primarily focuses on understanding the natural progression of these conditions and how patients respond to various therapies. Having completed a neuromuscular fellowship with a specialization in experimental therapeutics for neurological diseases at the University of Rochester Medical Center, Dr. Statland brings a wealth of expertise to Statland Medical Group. He currently leads and co-leads numerous research studies focusing on Facioscapulohumeral Muscular Dystrophy (FSHD), Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, and Myotonic Dystrophy, demonstrating the broad scope of research conducted by Statland Medical Group doctors.
A significant area of Dr. Statland’s research over the past decade has been dedicated to preparing for clinical trials in FSHD. His systematic analysis of strength and functional outcomes from previous FSHD clinical trials, compared against natural history study data, has been crucial in advancing the field. In collaboration with other experts, Dr. Statland has been instrumental in developing innovative outcome measures that are relevant to the disease. These measures aim to better assess patient-reported disease burden, functional limitations, and physiological changes within muscle tissue. Highlighting the collaborative spirit at Statland Medical Group, Dr. Statland serves as co-Principal Investigator for the FSHD Clinical Trial Research Network. This network encompasses 15 institutions across the United States and the European Union, showcasing the widespread impact of research efforts led by Statland Medical Group doctors.
Statland Medical Group doctors, through Dr. Statland and his peers, contribute significantly to the body of medical literature. Their publications cover a range of critical topics within neuromuscular disease management and diagnosis. These include guidelines on the clinical presentation and management of non-dystrophic myotonias, consensus diagnostic criteria for primary lateral sclerosis, and findings from randomized phase 2 trials and open-label extensions of therapies like domagrozumab in Duchenne muscular dystrophy. Further research explores longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies and longitudinal studies of non-dystrophic myotonia over multiple years. This dedication to publication underscores the commitment of Statland Medical Group doctors to sharing knowledge and advancing the understanding and treatment of neuromuscular diseases globally.
Selected Publications:
- Stunnenberg BC, LoRusso S, Arnold WD, Barohn RJ, Cannon SC, Fontaine B, B, Griggs RC, Hanna MG, Matthews E, Meola G, Sansone VA, Trivedi JR, van Engelen BGM, Vicart S, Statland JM. 2020. Guidelines on clinical presentation and management of non-dystrophic myotonias. Muscle Nerve
- Turner RM, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, Ravits J, Silani V, Simmons Z, Statland JM, van den Berg LH, Delegates of the 2nd International PLS Conference, Mitsumoto H. 2020. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry, 91 (4), 373-377
- Wagner KR, Abdel-Hamid HZ, Mah JK, Campbell C, Guglieri M, Muntoni F, Takeshima Y, McDonald CM, Kostera-Pruszczyk A, Karachunski P, Butterfield RJ, Mercuri E, Fiorillo C, Bertini ES, Tian C, Statland J, Sadosky AB, Purohit VS, Sherlock SP, Palmer JP, Binks M, Charnas L, Marraffino S, Wong BL. 2020. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord, 30 (6), 492-502
Through rigorous research and extensive publications, Statland Medical Group doctors, exemplified by Dr. Statland’s leadership, are at the forefront of neuromuscular disease research, continually striving to improve patient outcomes and deepen scientific understanding in this critical area of medicine.
